---
title: "Levosimendan - Congestive Heart Failure - 2"
sidebar: mydoc_sidebar
permalink: db00922-mesh-d006333-2.html
toc: false 
---


Path ID: `DB00922_MESH_D006333_2`
{% include image.html url="images/db00922-mesh-d006333-2.png" file="db00922-mesh-d006333-2.png" alt="db00922-mesh-d006333-2" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| <a href="https://identifiers.org/MESH:C076731">MESH:C076731 </a> | Levosimendan | Drug |
| <a href="https://identifiers.org/UniProt:Q14432">UniProt:Q14432 </a> | cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Protein |
| <a href="https://identifiers.org/CHEBI:17489">CHEBI:17489 </a> | 3',5'-cyclic AMP | ChemicalSubstance |
| <a href="https://identifiers.org/GO:0004679">GO:0004679 </a> | AMP-activated protein kinase activity | MolecularActivity |
| <a href="https://identifiers.org/GO:0005262">GO:0005262 </a> | Calcium channel activity | MolecularActivity |
| <a href="https://identifiers.org/GO:0070509">GO:0070509 </a> | Calcium ion import | BiologicalProcess |
| <a href="https://identifiers.org/GO:0060047">GO:0060047 </a> | Heart contraction | BiologicalProcess |
| <a href="https://identifiers.org/GO:0044557">GO:0044557 </a> | Relaxation of smooth muscle | BiologicalProcess |
| <a href="https://identifiers.org/GO:0042311">GO:0042311 </a> | Vasodilation | BiologicalProcess |
| <a href="https://identifiers.org/HP:0000822">HP:0000822 </a> | Hypertension | PhenotypicFeature |
| <a href="https://identifiers.org/MESH:D006333">MESH:D006333 </a> | Congestive heart failure | Disease |
|------------|------|---------|

## Relationships


NOTE: predicates are annotated in <a href="https://github.com/biolink/biolink-model/releases/tag/v1.3.0">Biolink Model (v1.3.0)</a>

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Levosimendan | DECREASES ACTIVITY OF | Cgmp-Inhibited 3',5'-Cyclic Phosphodiesterase A |
| Cgmp-Inhibited 3',5'-Cyclic Phosphodiesterase A | DECREASES ABUNDANCE OF | 3',5'-Cyclic Amp |
| 3',5'-Cyclic Amp | POSITIVELY REGULATES | Amp-Activated Protein Kinase Activity |
| Amp-Activated Protein Kinase Activity | POSITIVELY REGULATES | Calcium Channel Activity |
| Calcium Channel Activity | POSITIVELY REGULATES | Calcium Ion Import |
| Calcium Ion Import | POSITIVELY REGULATES | Heart Contraction |
| Heart Contraction | NEGATIVELY CORRELATED WITH | Congestive Heart Failure |
| 3',5'-Cyclic Amp | POSITIVELY REGULATES | Relaxation Of Smooth Muscle |
| Relaxation Of Smooth Muscle | POSITIVELY REGULATES | Vasodilation |
| Vasodilation | NEGATIVELY CORRELATED WITH | Hypertension |
| Hypertension | AFFECTS RISK FOR | Congestive Heart Failure |
|---------|-----------|---------|

Comment: Levosimendan has not been approved for use in the U.S. or Canada.  It has been reported that levosimendan may act preferentially as a Ca2+ sensitizer at lower concentrations, whereas at higher concentrations its action as a PDE-III inhibitor becomes more prominent in experimental animals and humans.

Reference: 
  - [https://go.drugbank.com/drugs/DB00922](https://go.drugbank.com/drugs/DB00922)
